GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (STU:NJT) » Definitions » EV-to-EBITDA

Regenetp (STU:NJT) EV-to-EBITDA : 0.31 (As of Jun. 07, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Regenetp EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Regenetp's enterprise value is €-2.27 Mil. Regenetp's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was €-7.34 Mil. Therefore, Regenetp's EV-to-EBITDA for today is 0.31.

The historical rank and industry rank for Regenetp's EV-to-EBITDA or its related term are showing as below:

STU:NJT's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.42
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-07), Regenetp's stock price is €0.0358. Regenetp's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was €-1.604. Therefore, Regenetp's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Regenetp EV-to-EBITDA Historical Data

The historical data trend for Regenetp's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp EV-to-EBITDA Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.77 -0.54 -0.49 -1.14 0.53

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 1.09 0.65 0.53 -0.03

Competitive Comparison of Regenetp's EV-to-EBITDA

For the Biotechnology subindustry, Regenetp's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenetp's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenetp's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Regenetp's EV-to-EBITDA falls into.



Regenetp EV-to-EBITDA Calculation

Regenetp's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-2.269/-7.339
=0.31

Regenetp's current Enterprise Value is €-2.27 Mil.
Regenetp's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regenetp  (STU:NJT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Regenetp's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0358/-1.604
=At Loss

Regenetp's share price for today is €0.0358.
Regenetp's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.604.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Regenetp EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Regenetp's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (STU:NJT) Business Description

Traded in Other Exchanges
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.

Regenetp (STU:NJT) Headlines

No Headlines